Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast cancers. A recently completed phase 3 clinical trial, conducted by ...

The outlook has been especially poor when the resistant ER-positive tumor is negative for a protein called HER2 — another important drug target — and carries a PIK3CA gene mutation. Now a phase 3 ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible treatment. Their decision is informed by a comprehensive molecular profile ...

This underscores the importance of testing for PIK3CA mutations prior to first-line treatment so that people with a poor prognosis can benefit from an effective, PI3K-targeted therapy as soon as ...

PIK3CA mutations are found in 35-40% of HR+ breast cancers. Prof Kristian Helin, chief executive of the Institute of Cancer Research, London, said: "One of the challenges with combination ...

We are exploring additional studies in breast cancer and other tumor types with the hope of providing the benefit of this targeted therapy to more people with PIK3CA mutations. About the INAVO120 ...